Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes' Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Biomanufacturing,” will showcase how AI, automation, and robotics are driving the new era of drug discovery and development.

GlobeNewsWire • Feb 23, 2026

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference - Monday, March 2, 2026 Leerink Partners 2026 Global Healthcare Conference - Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit — Wednesday, March 11, 2026 KeyBanc 2026 Healthcare Forum — Tuesday, March 17, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives.

GlobeNewsWire • Feb 23, 2026

What's in Store for These 5 Medical Companies This Earnings Season?

IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.

Zacks Investment Research • Feb 23, 2026

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT

GlobeNewsWire • Feb 18, 2026

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.53, indicating a +2.02% shift from the previous trading day.

Zacks Investment Research • Feb 18, 2026

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.

Nvidia disclosed in a filing on Tuesday that it no longer held shares in Applied Digital, drug-discovery company Recursion Pharmaceuticals and autonomous-driving company WeRide.

Barrons • Feb 18, 2026

2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off

AI-assisted drug discovery isn't just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age.

24/7 Wall Street • Feb 12, 2026

Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know

Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving 3.27% from the previous trading session.

Zacks Investment Research • Feb 10, 2026

This $4 Stock Could Be Your Ticket to Millionaire Status

It comes as no surprise that artificial intelligence is at the heart of the opportunity. This application of AI, in fact, is arguably one of the best uses of this young technology.

The Motley Fool • Feb 7, 2026

Recursion Pharmaceuticals (RXRX) Suffers a Larger Drop Than the General Market: Key Insights

In the closing of the recent trading day, Recursion Pharmaceuticals (RXRX) stood at $3.9, denoting a -4.88% move from the preceding trading day.

Zacks Investment Research • Feb 4, 2026